MAPT and supranuclear palsy, progressive, 1: In in vitro studies [18F]PI-2620 demonstrated its potential to bind to pathological tau aggregates/aggregate folds in both AD and non-AD tauopathies using AD and PSP brain sections (Figs. 4 and 5) as well as brain homogenates of PSP and PiD patients (Table 2).